Aim To investigate the effects of JAK inhibitor （SHR0302） on adjuvant-induced arthritis （AA） rats and the partial mechanisms focused on T, B lymphocyte subsets through JAK1-STAT3 pathway, including Thl7, Treg, tot...Aim To investigate the effects of JAK inhibitor （SHR0302） on adjuvant-induced arthritis （AA） rats and the partial mechanisms focused on T, B lymphocyte subsets through JAK1-STAT3 pathway, including Thl7, Treg, total B cells and memory B cells. Methods Animals were divided randomly into 6 groups including normal control, AA, SHR0302 （0.3, 1.0, 3.0 nag · kg^-1, ig） and MTX （0.5 nag · kg^-1 , ig） . The effects of SHR0302 on AA rats by evaluating arthritis index, arthritis global assessment and paw swelling degree, histopathology of joint and spleen, inflammatory cytokine and antibody production in serum. We examined the proliferation of T, B and FLS by CCK8 kit; Thl7, Treg, total B and memory B cell proportion was measured by flow cytometry; Cytokines TNF-αβ, IL-1β, IL-10, IL-17 and antibody IgG1, IgG2a levels in serum were measured by ELISA kits; The ex- pression of p-JAK1 and p-STAT3 was measured by Western blot analysis. Results SHR0302 suppressed the se- verity of AA rats by attenuating the arthritis index, arthritis global assessment and paw swelling degree, and allevia- ted histopathology of spleen and joint of AA rats. SHR0302 can inhibit the proliferation of T, B and FLS, and down-regulated cytokines TNF-α, IL-1β, IL-17 and antibody IgG1, IgG2a levels, and suppressed the proportion of Thl7 and total B, and inhibited JAK1-STAT3 phosphorylation; There was no significant effect on Treg function and memory B cell proportion. Conclusion SHR0302 may attenuate the severity of AA rats, partially through signifi- cantly reducing Thl7 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation.展开更多
目的:观察清肝泻火方对Graves病(GD)模型小鼠Th17细胞相关转录因子的影响,从免疫反应角度研究清肝泻火方治疗GD的作用机制,探讨该方治疗GD的新靶点。方法:选取雌性BALB/c小鼠80只,其中60只以表达TSHR-A亚单位的重组腺病毒免疫制备GD小...目的:观察清肝泻火方对Graves病(GD)模型小鼠Th17细胞相关转录因子的影响,从免疫反应角度研究清肝泻火方治疗GD的作用机制,探讨该方治疗GD的新靶点。方法:选取雌性BALB/c小鼠80只,其中60只以表达TSHR-A亚单位的重组腺病毒免疫制备GD小鼠模型,造模成功后按随机数字表法分为模型组、甲巯咪唑组和清肝泻火方组,每组各20只;剩余20只作为对照组。甲巯咪唑组每日灌服甲巯咪唑混悬液12 mg/kg,清肝泻火方组每日灌服清肝泻火方混悬液2 m L,对照组和模型组每日灌服蒸馏水2 m L,各组均连续干预30 d。采用放射免疫法(RIA)检测各组GD模型小鼠血清中游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)水平;酶联免疫吸附法检测各组GD模型小鼠血清中白细胞介素-17(IL-17)、白细胞介素-21(IL-21)水平。结果 :甲巯咪唑和清肝泻火方均可降低小鼠血清中FT3、FT4、TSH及IL-17、IL-21的表达水平,与模型组比较,差异有统计学意义(P<0.05)。结论:清肝泻火方能抑制Th17细胞相关转录因子的表达,从而抑制甲状腺自身的免疫炎症反应,促进GD小鼠甲状腺功能的恢复。展开更多
文摘Aim To investigate the effects of JAK inhibitor （SHR0302） on adjuvant-induced arthritis （AA） rats and the partial mechanisms focused on T, B lymphocyte subsets through JAK1-STAT3 pathway, including Thl7, Treg, total B cells and memory B cells. Methods Animals were divided randomly into 6 groups including normal control, AA, SHR0302 （0.3, 1.0, 3.0 nag · kg^-1, ig） and MTX （0.5 nag · kg^-1 , ig） . The effects of SHR0302 on AA rats by evaluating arthritis index, arthritis global assessment and paw swelling degree, histopathology of joint and spleen, inflammatory cytokine and antibody production in serum. We examined the proliferation of T, B and FLS by CCK8 kit; Thl7, Treg, total B and memory B cell proportion was measured by flow cytometry; Cytokines TNF-αβ, IL-1β, IL-10, IL-17 and antibody IgG1, IgG2a levels in serum were measured by ELISA kits; The ex- pression of p-JAK1 and p-STAT3 was measured by Western blot analysis. Results SHR0302 suppressed the se- verity of AA rats by attenuating the arthritis index, arthritis global assessment and paw swelling degree, and allevia- ted histopathology of spleen and joint of AA rats. SHR0302 can inhibit the proliferation of T, B and FLS, and down-regulated cytokines TNF-α, IL-1β, IL-17 and antibody IgG1, IgG2a levels, and suppressed the proportion of Thl7 and total B, and inhibited JAK1-STAT3 phosphorylation; There was no significant effect on Treg function and memory B cell proportion. Conclusion SHR0302 may attenuate the severity of AA rats, partially through signifi- cantly reducing Thl7 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation.
文摘目的:观察清肝泻火方对Graves病(GD)模型小鼠Th17细胞相关转录因子的影响,从免疫反应角度研究清肝泻火方治疗GD的作用机制,探讨该方治疗GD的新靶点。方法:选取雌性BALB/c小鼠80只,其中60只以表达TSHR-A亚单位的重组腺病毒免疫制备GD小鼠模型,造模成功后按随机数字表法分为模型组、甲巯咪唑组和清肝泻火方组,每组各20只;剩余20只作为对照组。甲巯咪唑组每日灌服甲巯咪唑混悬液12 mg/kg,清肝泻火方组每日灌服清肝泻火方混悬液2 m L,对照组和模型组每日灌服蒸馏水2 m L,各组均连续干预30 d。采用放射免疫法(RIA)检测各组GD模型小鼠血清中游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)水平;酶联免疫吸附法检测各组GD模型小鼠血清中白细胞介素-17(IL-17)、白细胞介素-21(IL-21)水平。结果 :甲巯咪唑和清肝泻火方均可降低小鼠血清中FT3、FT4、TSH及IL-17、IL-21的表达水平,与模型组比较,差异有统计学意义(P<0.05)。结论:清肝泻火方能抑制Th17细胞相关转录因子的表达,从而抑制甲状腺自身的免疫炎症反应,促进GD小鼠甲状腺功能的恢复。
